Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memory RT: Memantine +/- Raloxifene for Cognitive Preservation After Brain Radiation
NCT07470606Phase 2Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Jul 2026
- Primary completion
- Jul 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in cognitive impairment comparing Group A: Standard of Care with Group B: Standard of Care plus raloxifene (2 arms). Primary endpoint: Hippocampal volume changes at 48 weeks. Started Jul 2026; status: recruiting.
02
Drugs
raloxifene
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT07470606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470606.